Ross Moat
Corporate Officer/Principal presso KINIKSA PHARMACEUTICALS, LTD.
Patrimonio netto: 286 620 $ in data 30/04/2024
Posizioni attive di Ross Moat
Società | Posizione | Inizio | Fine |
---|---|---|---|
KINIKSA PHARMACEUTICALS, LTD. | Corporate Officer/Principal | 01/02/2021 | - |
Storia della carriera di Ross Moat
Precedenti posizioni note di Ross Moat
Società | Posizione | Inizio | Fine |
---|---|---|---|
AVEXIS INC | Vendite & Marketing | 01/05/2018 | 01/06/2019 |
SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | - | - |
Formazione di Ross Moat
Middlesex University | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 4 |
Regno Unito | 2 |
Posizioni
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Sales & Marketing | 1 |
Settori
Health Technology | 4 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
Aziende private | 2 |
---|---|
Synageva BioPharma Corp.
Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Novartis Gene Therapies, Inc.
Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
- Borsa valori
- Insiders
- Ross Moat
- Esperienza